Evidence map›Paper›PMID 34101898›Full record

ArticleJournal of clinical laboratory analysis2021

Analysis of the diagnostic capabilities of urinary neutrophil gelatinase-associated lipocalin and serum procalcitonin for acute kidney injury at the early stage of critical care intensive care unit admission.

Yuji Imoto, Ayano Wakasaki, Kumiko Izumida, Hiroshi Shimada, Kumiko Ohkubo, Yasumasa Kawano, Hiroyasu Ishikura, Akira Matsunaga

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical laboratory analysis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Right Heart Function in Cardiorenal Syndrome.Current heart failure reports · 2022
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Biomarkers in Cardiorenal Syndrome.Journal of clinical medicine · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yuji ImotoDepartment of Clinical Laboratory, Fukuoka University Hospital, Fukuoka, Japan.
Ayano WakasakiDepartment of Clinical Laboratory, Fukuoka University Hospital, Fukuoka, Japan.
Kumiko IzumidaDepartment of Clinical Laboratory, Fukuoka University Hospital, Fukuoka, Japan.
Hiroshi ShimadaDepartment of Clinical Laboratory, Fukuoka University Hospital, Fukuoka, Japan.
Kumiko OhkuboDepartment of Clinical Laboratory, Fukuoka University Hospital, Fukuoka, Japan.
Yasumasa KawanoDepartment of Emergency and Critical Care Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Hiroyasu IshikuraDepartment of Emergency and Critical Care Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Akira MatsunagaDepartment of Clinical Laboratory, Fukuoka University Hospital, Fukuoka, Japan.ORCID https://orcid.org/0000-0002-2192-3870
Fukuoka University · JPFukuoka University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute kidney injury (AKI) is a disease that negatively affects patient prognosis and requires early diagnosis and treatment. Biomarkers that predict AKI are needed for early diagnosis of this disease.

methodsWe compared the AKI group and the non-AKI group in patients who were admitted to our critical care intensive care unit (ICU) and conducted a comparative study focusing on urinary neutrophil gelatinase-associated lipocalin (U-NGAL) and serum procalcitonin (PCT).

resultsSeventy-one out of 106 ICU inpatients were diagnosed with AKI in accordance with the Kidney Disease: Improving Global Outcomes (KDIGO) criteria. Among the patients who were diagnosed with AKI stages 1 to 3, 94.4% of all patients reached the maximum stage by day 5 after admission. Comparing the non-AKI group and AKI stage 1 to 3 on days 1 to 3 after admission, U-NGAL and PCT levels in the stage 3 group were significantly higher than those in the non-AKI group. Additionally, in receiver operating characteristic curve (ROC) analysis on days 1-3 after admission, U-NGAL and PCT levels can be used as biomarkers for the diagnosis of AKI, and in particular, AKI stage 3 can be predicted and diagnosed with high accuracy. U-NGAL and PCT levels were also significantly higher in AKI due to sepsis and acute pancreatitis and due to sepsis, respectively.

conclusionsMeasuring U-NGAL and PCT levels as biomarkers for AKI may further improve the accuracy of AKI diagnosis in critical care ICU.

Indexed as

Critical CareHospitalizationIntensive Care UnitsAcute Kidney InjuryAgedAged, 80 and overBiomarkersCreatinineFemaleHumansLength of StayLipocalin-2MaleMiddle AgedProcalcitoninPrognosisBiomarkersCreatinineLCN2 protein, humanLipocalin-2Procalcitoninacute kidney InjuryNGALpancreatitisprocalcitoninsepsis

Identifiers

PMID34101898
PMCPMC8274979
OpenAlexW3172631196

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.